AstraZeneca's Innovative Cancer Study: A Potential Game-Changer?
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca's ongoing study, titled 'A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)', aims to evaluate the safety and effectiveness of AZD9574, alone and with other anti-cancer drugs, in patients with advanced cancers.
The study tests AZD9574, an experimental drug, both as a standalone treatment and in combination with other drugs like Temozolomide, Trastuzumab Deruxtecan, and Datopotamab Deruxtecan. These interventions target various advanced solid tumors, including breast, ovarian, pancreatic, and prostate cancers.
This interventional study is non-randomized and follows a sequential intervention model. It is open-label, meaning no masking is involved, and its primary purpose is treatment-focused. The study is designed to escalate doses to determine safety and efficacy.
Key dates for the study include its start on June 24, 2022, with the latest update submitted on July 23, 2025. These dates are crucial for tracking the study's progress and ensuring timely updates for stakeholders.
The study's progress could influence AstraZeneca's stock performance and investor sentiment, especially if the results show promising efficacy. As the study involves novel cancer treatments, it could impact the competitive landscape in oncology, potentially affecting other companies in the sector.
The study is currently recruiting, with further details available on the ClinicalTrials portal.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
8 hours ago
- Globe and Mail
Is QuantumScape Stock a Buy Now?
Key Points QuantumScape's solid-state lithium-metal battery technology aims to achieve higher energy density, faster charging, and improved safety compared to traditional lithium-ion batteries. The company has partnered with PowerCo, Volkswagen Group's battery manufacturing arm, to produce its technology and support a capital-light business model. Analysts predict that meaningful revenue won't materialize until 2027, with a surge forecast for 2028. 10 stocks we like better than QuantumScape › QuantumScape (NYSE: QS) is leading the charge to revolutionize energy storage with its innovative solid-state lithium-metal battery technology for electric vehicles and other applications. Its cutting-edge battery technology promises higher energy density and faster charging times, while also significantly improving safety compared to traditional lithium-ion batteries. The company has made headlines recently as its battery technology progresses, and the stock has surged 265% from its 52-week low. Here's what investors need to know about QuantumScape's investment prospects and what to expect from the company over the next several years. QuantumScape's battery technology ambitions Last year, QuantumScape partnered with PowerCo, the battery manufacturing arm of the Volkswagen Group. Volkswagen has been a significant investor in QuantumScape since 2012, committing around $380 million, and is the company's largest shareholder. QuantumScape's collaboration with PowerCo looks to advance its QSE-5 technology platform, with the goal of scaling up production at PowerCo's facilities. PowerCo is the "anchor customer" in QuantumScape's expanding technology ecosystem, as the company aims to develop a capital-light licensing model and expand its partnerships with customers worldwide. Instead of incurring heavy manufacturing investments, QuantumScape would license its technology to these partners, reducing its exposure to manufacturing risks and capital demands. QuantumScape is focused on broadening its range of potential licensing agreements with other automotive manufacturers. It also aims to strengthen its relationships with technology partners and key players across the battery value chain. This recent news sent the stock soaring One of QuantumScape's primary goals coming into 2025 was to bring the Cobra separator process into baseline production. Cobra represents a "step-change innovation in ceramics processing" designed to enable a significant improvement in separator productivity. This new process offers a 25 times improvement in heat treatment speed and requires only a fraction of the physical space per film start (compared to its prior-generation Raptor process). In June, the company announced that its Cobra separator process had reached baseline production, a key step toward commercializing its batteries. The successful baselining of Cobra is crucial for enabling higher-volume B1 sample production of their QSE-5 cells, which will be used in a launch program designed to showcase them, with field testing scheduled to commence in 2026. Since the announcement, the stock has surged 190%. Be mindful of the timeline and its finances One thing investors should be aware of regarding QuantumScape is that it is a company in its early growth stage. The company has not generated any revenue to date and continues to incur losses as it spends heavily on research and development. QuantumScape posted an operating loss of $123.6 million in the first quarter and expects to incur significant expenses and ongoing losses into the future. Capital expenditures in the first quarter of 2025 were $5.8 million, primarily supporting equipment and facilities for higher-volume QSE-5 B1 sample production using the Cobra separator process. The company's full-year capital expenditure guidance for 2025 is between $45 million and $75 million. QuantumScape reported $860.3 million in cash and equivalents at the end of the first quarter and anticipates this cash runway is enough to extend into 2028. This runway has expanded since it announced its licensing agreement with PowerCo, which is expected to lower costs and capital requirements compared to previous joint venture arrangements. Is QuantumScape a buy today? I'm excited about the potential of QuantumScape's groundbreaking battery technology, which has the potential to transform energy storage in the future. However, the company is still in the early stages of development and testing, and will continue to incur losses as it brings its vision to life. Analysts have noted that we should not expect meaningful revenue from QuantumScape until 2027, with projections of $51.6 million that year, followed by a significant leap to $265 million in 2028. Until then, we're looking at a story-driven stock that will attract attention but may not offer as much upside from here, especially given its recent surge. Should you invest $1,000 in QuantumScape right now? Before you buy stock in QuantumScape, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and QuantumScape wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* Now, it's worth noting Stock Advisor's total average return is 1,041% — a market-crushing outperformance compared to 183% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 21, 2025
CTV News
9 hours ago
- CTV News
Eric Ham: China's record purchases of Canadian crude could be a harbinger of more deals to come
Eric Ham on U.S. President Donald Trump saying a deal may not happen ahead of the August 1 deadline and Canada may be forced to 'just pay tariffs.'
CBC
10 hours ago
- CBC
What the U.S. dairy industry really wants from Canada
U.S. dairy producers insist they're not looking for Canada to dismantle its supply management system, but they do want Canada to follow the letter and spirit of the existing deal that governs the dairy trade between the two countries. U.S. President Donald Trump has repeatedly blasted Canada as "unfair" and "ripping us off" with massive dairy tariffs, in a way that isn't fully accurate. However, senior figures in the U.S. dairy industry are concerned there's also some misrepresentation happening north of the border, creating a false perception of what U.S. producers are actually seeking in terms of access to the Canadian market. Shawna Morris, executive vice-president for trade policy and global affairs with the National Milk Producers Federation and the U.S. Dairy Export Council, says it's not true that her industry wants Canada to abandon its system for protecting the dairy sector. "We've never been out to eliminate Canada's supply management," said Morris in an interview from her office in Arlington, Va., just outside Washington. "It's much easier to create a boogeyman and fear-mongering around that being the goal of the Americans, but that's certainly not what our industry has advocated." Becky Rasdall Vargas, senior vice-president of trade and workforce policy at the International Dairy Foods Association lobby group, says she recognizes the Trump administration has been "fairly abrasive" in its tone toward Canada. "But at the same time, I think we feel pretty ignored by Canada in terms of our legitimate trade concerns." Two main trade irritants According to Morris and Rasdall Vargas, the U.S. industry has two main irritants with Canada: how the Canadian government allocates the existing quotas for tariff-free imports of dairy products, and how Canadian milk producers dump cheap milk protein into the international market. The import quotas negotiated under the Canada-U.S.-Mexico Agreement (CUSMA, which Americans call USMCA) are designed to give U.S. producers tariff-free access worth roughly 3.5 per cent of Canada's domestic demand for dairy products. "Three per cent is pretty limited," said Morris. "It's certainly not a situation where our industry is gonna come in and take over the Canadian dairy market." CUSMA sets import quotas for 14 categories of dairy products. That allows an annual volume of each category to enter Canada tariff-free, and any imports exceeding the quota would get hit with sky-high tariffs of 200 per cent or more. Canada's rationale for this is ensuring the domestic dairy industry thrives by effectively capping how much the U.S. can export each year, preventing cheaper American products from dominating the market. The U.S. government supports its dairy sector with hefty direct subsidies. The U.S. dairy industry says it's not asking for Canada's quotas to be increased or the tariff rates to be decreased. Rather, it wants changes to how Ottawa allocates the quotas: more specifically, who gets them. Big Canadian dairies dominate import quotas Much of the quota volume is allocated to major Canadian-owned dairy processing companies such as Saputo and Agropur. Industry analysts on both sides of the border say such companies have little incentive to import U.S. products that would compete with their own. According to the U.S. producers, this restricts their access to the Canadian market. Their evidence for that claim: Canadian trade statistics showing tariff-free imports from the U.S. have almost never reached the quota limits in any category. WATCH | What Donald Trump gets wrong (and right) about Canada's dairy tariffs: Is Trump right about Canada charging 250% dairy tariffs? | About That 4 months ago President Donald Trump says Canada has been ripping off the United States, imposing tariffs of up to 400 per cent on imported American dairy products. Andrew Chang breaks down Trump's claims, explaining how dairy tariffs work and how likely it is that anyone is actually paying such sky-high charges. Images supplied by Reuters, Getty Images and The Canadian Press. Additional credits (Credit: 9:17 Skotidakis/Facebook), (Credit: 9:21 Elite Dairy). "For five years, Canada's been playing games with these tariff rate quotas," said Morris. "That's a lot of volume that should have been able to reach Canadian consumers." Despite those complaints, Canada's imports of U.S. dairy products have risen significantly since the CUSMA quotas took effect in 2020. Those imports totalled $897 million in 2024, according to Statistics Canada data, more than four times the value of imports in any year before 2020. "Trade certainly should be far higher than it is," said Morris. "That was what USMCA promised to deliver and quite frankly has fallen far short." A key change the U.S. producers would like to see is for Canada to grant retailers and the food-service sector a share of the tariff-free quotas, allowing them to import some U.S. dairy products directly. The U.S. industry also wants Canada to be far stricter in taking away allocations from importers that fail to use their full quota in a given year. While a bill that Parliament passed in June bars Ottawa from agreeing to raise the dairy import quotas or lower the tariffs, it doesn't prevent other changes to the system, leaving Canadian trade negotiators some wiggle room. WATCH | Canada's supply management system, explained: How Canada's dairy supply management system works — and why Trump hates it 6 months ago 'An inherent mismatch' The other chief complaint from the U.S. focuses on Canada's cheap exports of milk proteins, also described as milk solids, such as skim milk powder. The Americans argue that because Canada's supply management system keeps domestic prices artificially high, Canada can sell its excess production of milk proteins internationally at artificially low prices, undercutting the competition. "It frankly makes no sense that you could have one of the highest milk prices in the world and yet be exporting dairy protein at some of the lowest prices globally," said Morris. "That's just an inherent mismatch." Canada's pricing of milk solids for the export market is currently the subject of a U.S. International Trade Commission investigation, ordered by the Trump administration, with a hearing scheduled for Monday. Dairy Farmers of Canada declined a request for comment on the case. "During the recent election, all major parties expressed support for supply management and stated that it would be off the table in upcoming trade negotiations," the organization said in a news release in June. The Trump administration is not the first to accuse Canada of breaching CUSMA terms on dairy. Joe Biden's administration twice took legal action over Canada's handling of the dairy quotas, claiming it was unfairly undermining U.S. access to the Canadian market. The U.S. won the first dispute, which it launched in 2021, but failed to win the second, in 2023. Now in 2025, Rasdall Vargas says her industry wants Canada to be willing to hear its true concerns and do something about them. "Ultimately, when we have a trading partner who isn't taking our concerns seriously until they're threatened to do so, it's also not a good feeling from our side," she said. Whatever anyone thinks about Trump's bluster on Canadian dairy, Rasdall Vargas believes it's having an impact. "I think that's the president's way of having our back, probably more abrasively than Canada would like," she said.
